Theresa A. Guise, MD
The University of Texas M.D. Anderson Cancer Center
|Titles & Positions|
|Institutional & Related Links|
|Grant ID: RR190108|
Recruitment of Established Investigators
Indiana University School of Medicine
November 20, 2019
Theresa A. Guise, MD was recruited to The University of Texas M.D. Anderson Cancer Center from an Indiana University School of Medicine through a Recruitment of Established Investigators Award. She has a strong history of successful extramural funding, with continuous NIH support since 1993.
Throughout her career, Dr. Guise has made seminal contributions to our understanding of cancer effects on the musculoskeletal system, beginning with demonstrating the central role for tumor–secreted PTHrP, and its downstream mediator, RANKL, in osteolytic bone metastases. These studies were the first to provide the rationale for RANKL antibodies to treat bone metastases, now FDA approved for all solid tumor metastases to bone and multiple myeloma. She developed the first animal models of osteoblastic metastases that defined the causal role of endothelin-1, and described the role of bone-derived TGF Beta in promoting bone metastases of multiple solid tumors. She showed that bone microenvironment hypoxia enhanced TGF Beta signaling to promote bone metastases and identified an inhibitor of TGF Beta signaling, PMEPA1, which is regulated in prostate cancer and whose expression predicts metastases-free survival. Recently, she has shown that bone-derived TGF Beta induces oxidation of the skeletal muscle intracellular calcium release channel (ryanodine receptor) causing calcium leak & muscle weakness.